Venture capital investment in US biopharmaceutical companies fell $2.1bn from $9.89bn in 2015 to $7.79bn in 2016, but it was still the second highest amount of VC cash invested in US drug development firms since 2006, according to the Pitchbook-NVCA Venture Monitor.
The quarterly venture capital report is produced for the National Venture Capital Association (NVCA) by Pitchbook, which tracks VC and private equity investments as well as mergers and acquisitions